Hepatocellular carcinoma (HCC) with spontaneous rupture is a potentially fatal complication and usually has poor prognosis. In most conditions, the tumors could not be radically moved. Then minimally therapy like transcatheter arterial chemoembolization (TACE) could effectively stanch the ruptured tumor and bleeding vessels. Then TACE combined the Lenvatinib and PD-1 inhibitor for this subtype HCC could effectively inhibit the tumor and improve the prognosis.
diagnosis of primary HCC, confirmed histologically or clinically according to the criteria of the American Association for the Study of Liver Diseases;
presence of hemostasis in the enhanced CT scan;
integrity of the tumor is disrupted and there is hematoma around the liver;
receipt of Lenvatinib and PD-1 inhibitor as the first-line systemic therapy;
recurrent HCC;
non-ruptured HCC;
Lenvatinib and PD-1 inhibitor treated with as second systemic therapy;
age < 18 years or > 75 years;